echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > State Food and Drug Administration: stop production and sales of furazolidone containing compound preparations, involving 13 enterprises including Harbin Pharmaceutical and China Resources Sanjiu

    State Food and Drug Administration: stop production and sales of furazolidone containing compound preparations, involving 13 enterprises including Harbin Pharmaceutical and China Resources Sanjiu

    • Last Update: 2019-02-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today (February 15), the State Food and Drug Administration announced that according to Article 42 of the drug administration law of the people's Republic of China and Article 40 of the regulations for the implementation of the drug administration law of the people's Republic of China, after the reevaluation organized by the State Food and drug administration, it is believed that the compound preparation containing furazolidone has serious adverse reactions, and the risk of use in China is greater than the benefit From now on, the production, sale and use of the compound preparation containing furazolidone in China will be stopped, and the approval certificate of the drug will be revoked The manufacturer shall be responsible for the recall of the marketed compound preparations containing furazolidone, which shall be completed before March 31, 2019, and the recalled products shall be destroyed under the supervision of the local drug administration Furazolidone is a kind of nitrofuran antibacterial drug It has bactericidal effect by interfering with bacterial oxidoreductase It is a broad-spectrum antibacterial drug It has inhibitory effect on common gram-negative and positive bacteria It can be used to treat gastrointestinal diseases such as dysentery, enteritis and gastric ulcer caused by bacteria and protozoa In addition, according to the network information, excessive use of furazolidone may lead to gastrointestinal reactions (such as nausea, vomiting, anorexia, diarrhea, generally mild reaction); hemolytic anemia, rash, drug fever and other allergic reactions; multiple neuritis; lack of hemolytic anemia in newborns and g-6-ph If overdose or long-term continuous use of drugs, it can cause animal poisoning and even death It can cause irreversible damage to central nervous system and hemolytic liver necrosis in human body As early as 2002, the Ministry of agriculture listed it as a banned veterinary drug and prohibited its application in any food animals The FDA also banned the use of nitrofurans (including furazolidone) in animal food in 2002 However, in order to pursue economic benefits, some farmers still use it as a specific drug for the treatment of gastrointestinal diseases of aquatic products The study also showed that taking furazolidone for a long time or a high dose had different toxic and side effects on the liver, kidney, heart, hypothalamus and reproductive system of animals According to the pharmaceutical intelligence data, at present, there are 562 domestic furazolidone market approvals, 373 manufacturers, 547 of which are furazolidone tablets; in addition, according to the announcement annex, the banned compound preparations containing furazolidone are four varieties of compound xuedanfurazolidone capsule, furmatrine berberine tablet, two-dimensional furazolidone tablet and guhaisheng tablet, involving 13 enterprises, including compound xuedanfuran tablet Tanazolone capsule and guhaisheng tablet are the exclusive products of Guizhou Kehui pharmaceutical and China Resources Sanjiu (Ya'an) pharmaceutical respectively Source of the list of manufacturers of furazolidone containing compound preparations: State Food and drug administration, yaozhi.com and online public information statement: This article is the integrated content, and the opinion only represents the author, not the position of yaozhi.com Welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.